Airbnb, Inc. (ABNB) Stock Price Today
Replimune's melanoma drug gets FDA nod but faces legal probe over data practices
Replimune Group's melanoma drug Tudriqev received accelerated FDA approval after two prior rejections, based on a 24.20% response rate in trials. Following this, BMO Capital raised its price target for Replimune stock from $16 to $20, indicating stro...
Digital Realty backs Texas Governor Abbott's plan for responsible data center growth amid rising AI demand.
Digital Realty, the largest cloud- and carrier-neutral data center platform, supports Texas Governor Abbott's initiative for responsible and transparent data center investment in Texas. The company emphasizes collaboration with officials and communit...
Verisk Analytics CEO Lee Shavel sells 2,500 shares for $550,000.
Verisk Analytics CEO Lee Shavel has sold 2,500 shares of the company, generating $550,000 from the transaction. This sale may indicate personal portfolio adjustments or strategic financial planning by the CEO. Investors might watch for any further in...
Unity Software stock jumps after strong Q2 earnings and higher price target from Wells Fargo.
Unity Software reported strong Q2 results with revenue of $546.47 million, beating analyst estimates and showing a 24% year-over-year increase. The company posted an adjusted EPS of $0.28, a surprise profit compared to the expected loss. Wells Fargo ...
Replimune's stock jumps after FDA approves its first skin cancer drug Tudriqev
Replimune Group Inc. received FDA approval for Tudriqev, its first drug targeting a difficult form of skin cancer, marking a major milestone for the biotech company. Despite earlier rejections and concerns over clinical data quality, the FDA granted ...
Man Group PLC discloses 0.57% stake in Bodycote Plc, reducing long equity swap positions.
Man Group PLC has publicly disclosed holding a 0.57% interest in Bodycote Plc as of August 6, 2026. The disclosure reveals that Man Group is reducing its long positions through multiple equity swap transactions at varying prices. This update is part ...
Amylyx shifts focus to endocrine drug avexitide with strong cash runway into 2028 and key trial results in 2026
Amylyx Pharmaceuticals is transitioning from its previous focus on ALS treatments to developing avexitide, a late-stage endocrine drug targeting post-bariatric hypoglycemia, a large orphan market with no approved therapies. The company has $250.8 mil...
Tech stocks rally as weak July jobs report boosts SpaceX, Palantir, and Cloudflare shares.
Major tech stocks surged following a weaker-than-expected jobs report for July, which showed a drop in payrolls. SpaceX shares jumped 11% from a recent low, despite being down 16% since their June debut. Palantir rose 8.4%, continuing a strong weekly...
DraftKings' prediction markets drive rapid growth, reshaping its national sports betting strategy.
DraftKings has seen rapid growth in its prediction markets, with over 600,000 users and annualized trading volume jumping from $2.3 billion to $11 billion between April and July 2026. This expansion allows DraftKings to engage customers nationwide, i...
Akamai reports Q2 results near expectations with mixed revenue trends and margin pressure from CIS investments
Akamai Technologies reported Q2 results on August 6, showing revenue growth that met Wall Street expectations. The company experienced slowing delivery revenues but saw accelerating growth in its Cloud Intelligence Services (CIS) segment. Margin pres...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.